Moreover, this is the first study that explores the effectof a Cu2+ chelator with therapeutic potential for AD onCu2+ coordination to PrPC (an emerging key playerin AD pathology), integrating recent knowledge about metalloproteinsinvolved in AD with the design of copper chelators against AD. The gene discussed is PRNP; the disease is Alzheimer disease.